443 related articles for article (PubMed ID: 10556948)
1. Mechanisms underlying the impairment of endothelium-dependent relaxation in the pulmonary artery of monocrotaline-induced pulmonary hypertensive rats.
Nakazawa H; Hori M; Ozaki H; Karaki H
Br J Pharmacol; 1999 Nov; 128(5):1098-104. PubMed ID: 10556948
[TBL] [Abstract][Full Text] [Related]
2. Effects of atorvastatin and L-arginine treatments on electrical field stimulation-mediated relaxations in pulmonary arterial rings of monocrotaline-induced pulmonary hypertensive rats.
Ozturk EI; Uma S
J Cardiovasc Pharmacol; 2010 Nov; 56(5):498-505. PubMed ID: 20729759
[TBL] [Abstract][Full Text] [Related]
3. [TRPC6 mediates the enhancements of pulmonary arterial tone and intracellular Ca2+ concentration of pulmonary arterial smooth muscle cells in pulmonary hypertension rats].
Zhang MF; Liu XR; Yang N; Lin MJ
Sheng Li Xue Bao; 2010 Feb; 62(1):55-62. PubMed ID: 20179889
[TBL] [Abstract][Full Text] [Related]
4. Activity of endothelium-derived hyperpolarizing factor is augmented in monocrotaline-induced pulmonary hypertension of rat lungs.
Morio Y; Homma N; Takahashi H; Yamamoto A; Nagaoka T; Sato K; Muramatsu M; Fukuchi Y
J Vasc Res; 2007; 44(4):325-35. PubMed ID: 17438361
[TBL] [Abstract][Full Text] [Related]
5. Amlodipine prevents monocrotaline-induced pulmonary arterial hypertension and prolongs survival in rats independent of blood pressure lowering.
Mawatari E; Hongo M; Sakai A; Terasawa F; Takahashi M; Yazaki Y; Kinoshita O; Ikeda U
Clin Exp Pharmacol Physiol; 2007 Jul; 34(7):594-600. PubMed ID: 17581214
[TBL] [Abstract][Full Text] [Related]
6. Role of nitric oxide and endothelin-1 in monocrotaline-induced pulmonary hypertension in rats.
Mathew R; Zeballos GA; Tun H; Gewitz MH
Cardiovasc Res; 1995 Nov; 30(5):739-46. PubMed ID: 8595621
[TBL] [Abstract][Full Text] [Related]
7. Endothelial nitric oxide synthase-enhancing G-protein coupled receptor antagonist inhibits pulmonary artery hypertension by endothelin-1-dependent and endothelin-1-independent pathways in a monocrotaline model.
Liu CP; Dai ZK; Huang CH; Yeh JL; Wu BN; Wu JR; Chen IJ
Kaohsiung J Med Sci; 2014 Jun; 30(6):267-78. PubMed ID: 24835346
[TBL] [Abstract][Full Text] [Related]
8. Attenuation of monocrotaline-induced pulmonary arterial hypertension in rats by rosuvastatin.
Li XL; Guan RJ; Li JJ
J Cardiovasc Pharmacol; 2012 Aug; 60(2):219-26. PubMed ID: 22592772
[TBL] [Abstract][Full Text] [Related]
9. Improvement of mortality by long-term E4010 treatment in monocrotaline-induced pulmonary hypertensive rats.
Kodama K; Adachi H
J Pharmacol Exp Ther; 1999 Aug; 290(2):748-52. PubMed ID: 10411587
[TBL] [Abstract][Full Text] [Related]
10. [Effects of rosuvastatin on monocrotaline-induced pulmonary artery hypertension in rats].
Li XL; Guan RJ; Xu QH; Wu ZY
Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Mar; 39(3):247-53. PubMed ID: 21609531
[TBL] [Abstract][Full Text] [Related]
11. L-arginine restores endothelial nitric oxide synthase-coupled activity and attenuates monocrotaline-induced pulmonary artery hypertension in rats.
Ou ZJ; Wei W; Huang DD; Luo W; Luo D; Wang ZP; Zhang X; Ou JS
Am J Physiol Endocrinol Metab; 2010 Jun; 298(6):E1131-9. PubMed ID: 20215577
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin-converting enzyme 2 activation ameliorates pulmonary endothelial dysfunction in rats with pulmonary arterial hypertension through mediating phosphorylation of endothelial nitric oxide synthase.
Li G; Zhang H; Zhao L; Zhang Y; Yan D; Liu Y
J Am Soc Hypertens; 2017 Dec; 11(12):842-852. PubMed ID: 29146157
[TBL] [Abstract][Full Text] [Related]
13. Decreased endothelial nitric-oxide synthase (eNOS) activity resulting from abnormal interaction between eNOS and its regulatory proteins in hypoxia-induced pulmonary hypertension.
Murata T; Sato K; Hori M; Ozaki H; Karaki H
J Biol Chem; 2002 Nov; 277(46):44085-92. PubMed ID: 12185080
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib alleviates experimental pulmonary arterial hypertension.
Kim SY; Lee JH; Huh JW; Kim HJ; Park MK; Ro JY; Oh YM; Lee SD; Lee YS
Am J Respir Cell Mol Biol; 2012 Nov; 47(5):698-708. PubMed ID: 22842494
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin-converting enzyme inhibitor preserves p21 and endothelial nitric oxide synthase expression in monocrotaline-induced pulmonary arterial hypertension in rats.
Kanno S; Wu YJ; Lee PC; Billiar TR; Ho C
Circulation; 2001 Aug; 104(8):945-50. PubMed ID: 11514384
[TBL] [Abstract][Full Text] [Related]
16. Genistein, a phytoestrogen, attenuates monocrotaline-induced pulmonary hypertension.
Homma N; Morio Y; Takahashi H; Yamamoto A; Suzuki T; Sato K; Muramatsu M; Fukuchi Y
Respiration; 2006; 73(1):105-12. PubMed ID: 16432296
[TBL] [Abstract][Full Text] [Related]
17. Tetrandrine prevents monocrotaline-induced pulmonary arterial hypertension in rats through regulation of the protein expression of inducible nitric oxide synthase and cyclic guanosine monophosphate-dependent protein kinase type 1.
Wang X; Yang Y; Yang D; Tong G; Lv S; Lin X; Chen C; Dong W
J Vasc Surg; 2016 Nov; 64(5):1468-1477. PubMed ID: 26527422
[TBL] [Abstract][Full Text] [Related]
18. Essential role of nitric oxide in sepsis-induced impairment of endothelium-derived hyperpolarizing factor-mediated relaxation in rat pulmonary artery.
Subramani J; Leo MD; Kathirvel K; Arunadevi R; Singh TU; Prakash VR; Mishra SK
Eur J Pharmacol; 2010 Mar; 630(1-3):84-91. PubMed ID: 20035746
[TBL] [Abstract][Full Text] [Related]
19. Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease.
Zhao YD; Courtman DW; Deng Y; Kugathasan L; Zhang Q; Stewart DJ
Circ Res; 2005 Mar; 96(4):442-50. PubMed ID: 15692087
[TBL] [Abstract][Full Text] [Related]
20. The HMG-CoA reductase inhibitor, pravastatin, prevents the development of monocrotaline-induced pulmonary hypertension in the rat through reduction of endothelial cell apoptosis and overexpression of eNOS.
Guerard P; Rakotoniaina Z; Goirand F; Rochette L; Dumas M; Lirussi F; Bardou M
Naunyn Schmiedebergs Arch Pharmacol; 2006 Sep; 373(6):401-14. PubMed ID: 16896805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
